HBV is a DNA virus. Eight genotypes of HBV have been identified and labeled A through H, Genotype D being most common in pakistan. I tried to compile key points from AASLD management guidelines. Taking treatment decision requires concept of different phases of chronic Hepatitis B infection so first we will discuss these four phases and then key points for the management of chronic hepatitis B infection.
Phases Of Chronic Hepatitis B Infection:
Chronic Hep B:
◦Positive for the hepatitis B virus (HBsAg) for more than six months
There are four Phases Of Chronic Hep B Infection
1. Immune tolerant Phase
2. Immune active Phase:
3. Inactive (Immune Control) Phase:
4. Immune Escape Phase:
Indications for treatment:
◦clearance of HBV DNA
◦normalization of liver enzymes.
Duration Of Treatment:
Hepatitis B in pregnancy:
There is either HBV dominance, which means high HBV DNA levels and low HCV RNA levels or HCV dominance defined by the high HCV RNA levels and low HBV DNA.
HBV Dominance – treat HBV
HCV Dominance – treat HCV
AASLD Guidelines: American Association for the Study of Liver Diseases
About The Author: Usman
M Usman Javed is the CEO and Founder of MedArcade.com. With a long time passion for Entrepreneurship, Self-development & Success, Usman started his website with the intention of educating and inspiring likeminded people all over the world to always strive for success no matter what their circumstances. Usman’s passion for what he does shows through the continual growth of MedArcade.com's online community. Connect with him on LinkedIn or keep upto date by subscribing this website through the box at About page.
In the previous guideline, groups were specified for
which surveillance was likely to be cost-effective
because the hepatocellular carcinoma (HCC) incidence
was high enough. New data on defining HCC risk
have emerged for hepatitis B virus,1,2 hepatitis C virus,
3 and autoimmune hepatitis.4 Surveillance is
deemed cost-effective if the expected HCC risk exceeds
1.5% per year in patients with hepatitis C and 0.2%
per year in patients with hepatitis B.
The AASLD/IDSA/IAS–USA hepatitis C Guidance addresses management issues ranging from testing and linkage to care, the crucial first steps toward improving health outcomes for HCV-infected persons, to the optimal treatment regimen in particular patient situations. Recommendations are based on evidence and are rapidly updated as new data from peer-reviewed evidence become available. For each treatment
option, recommendations reflect the best possible management for a given patient and a given point of
disease progression. Recommendations are graded with regard to the level of the evidence and strength of the recommendation. The AASLD/IDSA/IAS–USA hepatitis C Guidance is supported by the membershipbased societies and not by pharmaceutical companies or other commercial interests.
Get More Stuff Like This In Your Inbox